Fragasso Financial Advisors Inc Sells 47 Shares of Danaher Co. (NYSE:DHR)

Fragasso Financial Advisors Inc decreased its position in shares of Danaher Co. (NYSE:DHR) by 4.1% during the 4th quarter, Holdings Channel reports. The fund owned 1,099 shares of the conglomerate’s stock after selling 47 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Danaher were worth $252,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of DHR. Fort Pitt Capital Group LLC grew its holdings in shares of Danaher by 3.2% in the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC acquired a new position in Danaher in the third quarter valued at about $217,000. Harvest Portfolios Group Inc. increased its holdings in shares of Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares in the last quarter. ORG Partners LLC raised its position in shares of Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares during the period. Finally, Stifel Financial Corp lifted its holdings in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $239.83 on Tuesday. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70. The stock has a 50 day moving average of $235.52 and a 200-day moving average of $253.65. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $173.22 billion, a P/E ratio of 45.77, a P/E/G ratio of 4.32 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 earnings per share. As a group, equities research analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

Several analysts have commented on DHR shares. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Evercore ISI lifted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.